Author's Accepted Manuscript

for post-menopausal **Treatments** osteoporotic women, what's new? How can we manage longterm treatment?

Soledad Herrero, Yolanda Pico



PII: S0014-2999(16)30098-X

DOI: http://dx.doi.org/10.1016/j.ejphar.2016.02.053

EJP70487 Reference:

To appear in: European Journal of Pharmacology

Received date: 22 January 2016 Revised date: 19 February 2016 Accepted date: 23 February 2016

Cite this article as: Soledad Herrero and Yolanda Pico, Treatments for postmenopausal osteoporotic women, what's new? How can we manage long-tern treatment?, European Journal **Pharmacology** of http://dx.doi.org/10.1016/j.ejphar.2016.02.053

This is a PDF file of an unedited manuscript that has been accepted fo publication. As a service to our customers we are providing this early version o the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain Treatments for post-menopausal osteoporotic women, what's new? How can we manage long-term treatment?

Soledad Herrero, PharmD*, Yolanda Pico, PhD

Food and Environmental Research Group (SAMA-UV), Department of Preventive Medicine, Faculty of Pharmacy, University of Valencia, Vicent Andrés Estellés Avenue, without number Zip-code: 46100 Burjassot, València, Spain.

*Corresponding Author: Soledad Herrero: Phone number: +34963543092; Fax number: +34963544954 E-mail: sohero@hotmail.com

Abstract

Since the mid-1980s, postmenopausal osteoporosis (PMO) has been considered a serious public health concern because of the associated fractures. Pharmacological therapies that effectively reduce the number of fractures by improving bone mass have been and are being developed continuously. Most current agents inhibit bone loss by reducing bone resorption, but emerging therapies may increase bone mass by stimulating bone formation. Furthermore, nowadays, the most representative pharmaceuticals have been prescribed long enough to include the reporting of some adverse effects. This review discusses osteoporotic drugs that are approved or are under investigation for the treatment of post-menopausal women (PMW), paying particular attention to long-term treatments.

Keywords:

Download English Version:

https://daneshyari.com/en/article/5826770

Download Persian Version:

https://daneshyari.com/article/5826770

<u>Daneshyari.com</u>